Miami, FL – August 10, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Glucose Health, Inc. (OTC Pink: GLUC).
A smart insulin pen is your personal diabetes companion that keeps track of your dose data, so you don’t have to.
Business Insider, in January stated that the global smart insulin pen and pumps markets size is expected to reach US $6.3 billion by 2026 registering around a 10% CARG over the forecast period.
A key player in the space is Roche (OTC Pink: RHHBY), however in September 2019, Medtronic collaborated with Novo Nordisk to integrate Novo future smart insulin pen dosage data with Medtronic CGM devices.
Other players in the insulin market are Boston Scientific (NYSE: BSX) and Sanofi (NYSE: SNY).
If we are focusing only on growth and profitability…a smarter way to get into the space could be diabetic nutrition. Pharmaceutical giant Abbott Labs is the leader in diabetic nutrition with its Glucerna brand.
However, take a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®. GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
Glucose Health, Inc. (OTC Pink: GLUC) just announced triple-digit sales increases at Amazon (NASDAQ: AMZN) as its diabetic customers increasingly buy GLUCODOWN® during COVID-19. GLUCODOWN® is also sold nationwide in-store at Walmart pharmacies (NYSE: WMT), now the third largest pharmacy retailer after Walgreens and CVS.
What are the sales of this company going to look like when the latest GLUCODOWN® sales numbers from Amazon and Walmart come on the books during Q2 and Q3?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.